FDA Grants Fast Track Designation to PI3K Inhibitor ME-401 for Patients with FL

The FDA granted fast track designation to ME-401, an investigational selective oral inhibitor of PI3K delta, for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Source: CancerNetwork - April 3, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news